diethyl 4-chloro-1H-pyrazole-3,5-dicarboxylate | 1382786-13-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: diethyl 4-chloro-1H-pyrazole-3,5-dicarboxylate
• 英文别名: 4-chloro-1H-pyrazole-3,5-dicarboxylic acid diethyl ester
• CAS: 1382786-13-1
• 化学式: C₉H₁₁ClN₂O₄
• 分子量: 246.65
• InChiKey: YXEXOFBUDQKVMA-UHFFFAOYSA-N

物化性质

• 沸点：
  380.7±37.0 °C(Predicted)
• 密度：
  1.357±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  81.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  diethyl 4-chloro-1H-pyrazole-3,5-dicarboxylate 在 盐酸 、 caesium carbonate 、 potassium iodide 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 diethyl 1-(3-aminopropyl)-4-chloropyrazole-3,5-dicarboxylate hydrochloride
  参考文献：
  名称：

  [EN] PYRIMIDINE BASED MODULATORS AND USES THEREOF
  [FR] MODULATEURS À BASE DE PYRIMIDINE ET LEURS UTILISATIONS

  摘要：

  Provided herein are compounds, such as compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salts of any one there, useful for modulating KRAS GD12 and/or other G12 mutants.

  公开号：

  WO2023230190A1
• 作为产物：
  描述：

  3,5-吡唑羧酸二乙酯 在 sodium hypochlorite 、 溶剂黄146 作用下， 反应 16.0h， 以66%的产率得到diethyl 4-chloro-1H-pyrazole-3,5-dicarboxylate
  参考文献：
  名称：

  [EN] BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
  [FR] UTILISATION DE LACTAMES DE TRIAZOLE ET DE PYRAZOLE BICYCLIQUES COMME MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MGLUR5

  摘要：

  在一个方面，该发明涉及到双环三唑和吡唑内酰胺，它们的衍生物以及相关化合物，这些化合物可用作代谢型谷氨酸受体亚型5（mGluR5）的正向变构调节剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神疾病的方法。本摘要旨在作为在特定领域进行搜索的扫描工具，并不意味着对本发明的限制。

  公开号：

  WO2012083224A1

文献信息

• [EN] SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE SUBSTITUÉS
  申请人：BAYER AG

  公开号：WO2019219517A1

  公开（公告）日：2019-11-21

  The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.

  这项发明涉及替代二氢吡唑吡嗪羧酰胺衍生物，以及它们的制备方法，还涉及它们用于制备治疗和/或预防疾病的药物，特别是心血管疾病，优选为血栓性或血栓栓塞性疾病，糖尿病，以及泌尿生殖和眼科疾病。
• BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
  申请人：Conn P. Jeffrey

  公开号：US20120225844A1

  公开（公告）日：2012-09-06

  In one aspect, the invention relates to bicyclic triazole and pyrazole lactams, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及双环三唑和吡唑内酰胺、其衍生物和相关化合物，可作为代谢型谷氨酸受体亚型5（mGluR5）的正向变构调节剂；制备这些化合物的合成方法；包含这些化合物的制药组合物；以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神障碍的方法。本摘要旨在作为特定领域搜索的扫描工具，不限制本发明。
• Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors
  申请人：Conn P. Jeffrey

  公开号：US08592422B2

  公开（公告）日：2013-11-26

  In one aspect, the invention relates to bicyclic triazole and pyrazole lactams, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在某个方面，本发明涉及用作代谢型谷氨酸受体亚型5（mGluR5）正向变构调节剂的双环三唑和吡唑烯酮及其衍生物和相关化合物；制备该化合物的合成方法；包含该化合物的制药组合物；以及使用该化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神障碍的方法。本摘要旨在作为特定领域搜索的扫描工具，不限制本发明。
• [EN] PIPERAZINE DERIVATIVE AND USE THEREOF IN MEDICINE<br/>[FR] DÉRIVÉ DE PIPÉRAZINE ET SON UTILISATION EN MÉDECINE<br/>[ZH] 哌嗪衍生物及其在医药上的应用
  申请人：[en]CHENGDU BAIYU PHARMACEUTICAL CO., LTD.;[zh]成都百裕制药股份有限公司

  公开号：WO2022242750A1

  公开（公告）日：2022-11-24

  涉及哌嗪类化合物及其组合物以及其在制备抗肿瘤药物中的用途。
• Preliminary investigation of 6,7-dihydropyrazolo[1,5- a ]pyrazin-4-one derivatives as a novel series of mGlu 5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia
  作者：Susana Conde-Ceide、Jesús Alcázar、Sergio A. Alonso de Diego、Silvia López、María Luz Martín-Martín、Carlos M. Martínez-Viturro、Miguel-Angel Pena、Han Min Tong、Hilde Lavreysen、Claire Mackie、Thomas M. Bridges、J. Scott Daniels、Colleen M. Niswender、Carrie K. Jones、Gregor J. Macdonald、Thomas Steckler、P. Jeffrey Conn、Shaun R. Stauffer、Craig W. Lindsley、José Manuel Bartolomé-Nebreda

  DOI：10.1016/j.bmcl.2015.11.098

  日期：2016.1

  As part of our efforts to identify a suitable back-up compound to our recently disclosed mGlu(5) positive allosteric modulator (PAM) clinical candidate VU0490551/JNJ-46778212, this letter details the investigation and challenges of a novel series of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives. From these efforts, compound 4k emerged as a potent and selective mGlu(5) PAM displaying overall attractive in vitro (pharmacological and ADMET) and PK profiles combined with in vivo efficacy in preclinical models of schizophrenia. However, further advancement of the compound was precluded due to severely limiting CNS-related side-effects confirming the previously reported association between excessive mGlu(5) activation and target-related toxicities. (C) 2015 Elsevier Ltd. All rights reserved.